Influence of Intravesical Bacillus Calmette-Guerin Therapy on Systemic Immunological Status

This publication has 13 references indexed in Scilit:

• Bacillus Calmette-Gu rin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients
  Cancer Immunology, Immunotherapy, 1994
• Bacillus Calmette-Guérin Sensitises Fresh Transitional Carcinoma Cells and T24 Cell Line to Non-MHC-restricted Cytotoxicityin vitro
  British Journal of Urology, 1993
• Expansion of Peripheral Blood Natural Killer Cells Correlates with Clinical Outcome in Cancer Patients Receiving Recombinant Subcutaneous lnterleukin-2 and Interferon-α-2
  Tumor Biology, 1993
• Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer
  Cancer Immunology, Immunotherapy, 1992
• Effects of bacillus calmette-guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer
  Cancer, 1992
• Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin
  Cancer Immunology, Immunotherapy, 1991
• Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer
  Urological Research, 1991
• Intravesical Bcg Therapy in Bladder Carcinoma:Effect on Cytotoxicity, IL-2 Production and Phenotype of Peripheral Blood Mononuclear Cells
  Scandinavian Journal of Urology and Nephrology, 1991
• Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder Cancer
  Journal of Urology, 1988
• Detection of Interleukin 2 in the Urine of Patients with Superficial Bladder Tumors after Treatment with Intravesical BCG
  Journal of Urology, 1986